Objectives: The aim of this study was to evaluate the effects of implantation of a left ventricular assist system (LVAS) on the neurohormonal status, exercise capacity and symptomatic state in patients with severe congestive heart failure (CHF). Background: Severe CHF is characterized by decreased exercise tolerance and activation of several neurohormonal systems. Methods: Parameters of neurohormonal activation and exercise capacity in patients with LVAS (n=7) were compared with those in groups of New York Heart Association (NYHA) class 3 (n=121) and class 4 (n=81) patients. Plasma levels of norepinephrine (NE), plasma renin activity (PRA), and atrial natriuretic peptide (ANP) and maximal and submaximal exercise capacities were measured monthly in LVAS patients and compared with results in CHF patients. Results: Plasma NE and PRA levels were significantly lower in LVAS patients than in NYHA class 4 patients, and plasma ANP levels in LVAS patients were significantly lower than those in NYHA class 3 and 4 patients.
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(ongestive heart failure (CHF) is characterized by decreased exercise tolerance and neurohormonal activation including sympathetic nervous system stimulation, activation of the renin-angiotensin-system, and increased secretion of atrial natriuretic peptide (ANP). Improvement in cardiac pump function by cardiac transplantation is associated with partial reversal of these abnormalities."12 The Plasma NE and PRA levels were significantly lower in the LVAS patients compared with values of the NYHA class 4 patients. The NE levels also were significantly lower in the NYHA class 3 patients compared with NYHA class 4 patients (Fig 1, a and  b) . Plasma ANP levels were significantly lower in the LVAS patients compared with both NYHA class 3 and class 4 patient groups (Fig 1, c) . Figure 2 displays the plasma levels of NE, PRA, and ANP over time in the LVAS patients and compares them with values of the NYHA class 3 and 4 groups. The 3 patients in the LVAS group who demonstrated increased PRA at 1 month were not receiving angiotensin-converting enzyme inhibitors at the time of blood sampling, but all 3 patients were taking loop diuretics.
The distance walked during submaximal exercise test and the peak oxygen consumption during the maximal exercise stress test were similar for the LVAS and NYHA class 3 patients (Fig 3) . The NYHA class 4 CHF patients were unable to perform either submaximal or maximal exercise studies. these results with values of the NYHA class 3 group. The exercise tolerance in the LVAS group tended to improve progressively over time.
DISCUSSION
The results of this study demonstrate significant differences in neurohormonal activation and exercise capacity in patients who had implantation of a LVAS compared with groups of patients with severe heart failure. A previous study of three heart failure patients on asynchronous LVAS demonstrated improved exercise capacity as measured by oxygen consumption and increased cardiac output and heart rate during supine bicycle exercise 1 month after LVAS implantation.7
The level of sympathetic nervous system activation in heart failure may correlate with hemodynamic abnormalities, but this finding is not universally ac- proves end-organ blood flow and allows resolution of multiorgan (renal, hepatic, and pulmonary) dysfunction in up to half of the patients on the device. The increased blood flow and the attenuation of the neurohumoral excitatory state may enhance baroreceptor responsiveness. Improvement in organ blood flow, particularly to the skeletal muscle and kidneys, will inhibit afferent sympathetic signals and decrease efferent nerve traffic.'2 The LVAS is likely responsible for a decrease in plasma renin activity by improved renal blood flow, inhibiting renin release from the afferent arteriole and decreasing sympathetic activation. The increase in sodium excretion also will inhibit renin release from the macula densa. The diminution in sympathetic nerve traffic to the juxtaglomerular apparatus will decrease sympathetically mediated renal renin release.
Plasma ANP levels are elevated and related to the clinical and hemodynamic severity of CHF, particularly the level of right and left atrial pressures. (chronic implantation), it has the capability, in addition to improving systemic blood flow, of favorably affecting exercise and neurohormonal abnormalities characteristic of the heart failure state and making patients better candidates for cardiac transplantation.
